Nov 09, 2022
Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs
Aug 01, 2022
Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th
Displaying 1 - 10 of 15
Dec 11, 2022 at 6:00 PM - 8:00 PM CST
An abstract (Abstract# 3334) titled, "A Phase1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients with Advanced Hematologic and Solid Tumor Malignancies," will be presented as a trial-in-progress presentation.
Dec 12, 2022 at 6:00 PM - 8:00 PM CST
An abstract (Abstract# 4633) titled, "Phase 1/1b Safety Study of PRGN-3006 UltraCAR-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes," will be presented as a poster presentation.